MedicineAccess
We're building a rare disease company that is deliberate and purposeful in its approach.
We are agile and identify new opportunities to broaden patient access to new and existing medicines.
We move quickly and cost-effectively to rapidly commercialise medicines.
We are curious and energetic with a problem-solving mindset.
We use new ways of working to create value and support scale-up.
Our Team
An experienced, entrepreneurial team united by a shared mission to make a measurable difference in rare diseases. Meet the board:
Ahmed Al-Derzi
CEO & Co-Founder
Ahmed has over 30 years of experience as an entrepreneur and business leader in generic and speciality medicines.
Ahmed Al-Derzi
CEO & Co-Founder
Ahmed is an experienced entrepreneur and business leader in the commercialisation of generic and specialty medicines across Europe. He previously co-founded and lead a profitable European Speciality company.
John Irwin
Chief Commercial Officer & Co-Founder
John has more that 25 years of experience in value creation across orphan medicines and rare disease.
John Irwin
Chief Commercial Officer & Co-Founder
He's a seasoned leader in pre-commercial asset value development, commercial launch planning, and pricing and market access for orphan medicines. John brings a strong track record of delivering successful launches and creating value for companies across multiple geographies and therapeutic areas.
Dr Kieran Rooney
Non-Executive Director
Kieran brings over 30 years of experience in corporate and business development across biopharma, with expertise in rare disease.
Dr Kieran Rooney
Non-Executive Director
As Senior Vice President and Head of Business Development at Amryt Pharma, Keiran led the acquisitions of Aegerion Pharmaceuticals and Chiasma, and most recently played a key role in the sale of Amryt to Chiesi, one of Europe's most successful biopharma exits of the past decade.
Values that shape how we work
Compassion, Respect & Humility
We put patients and people first, listening carefully, acting with empathy, and recognising that meaningful impact starts with respect.
Openness & Diversity of Thought
We value different perspectives and experiences, knowing that better decisions come from open dialogue and inclusive thinking.
Innovation & Challenge
We challenge convention and apply fresh thinking to solve complex problems, always focused on creating practical impact.
Collaboration & Meaningful Work
We work together with purpose, supporting one another to deliver work that matters for patients, healthcare systems and commercial partners.
OTD-NP-GBR-00002 | March 2026